Eli Lilly & Co. (LLY) reports tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Eli Lilly & Co. (LLY) reports tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

August 1, 2024 6:45 AM EDT

Tirzepatide reduced the risk of heart failure outcomes heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death by 38% compared to placebo

Tirzepatide significantly improved heart failure symptoms and physical limitations

Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes 

INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and... More